TCT 2016: EXCEL And NOBLE Give Different Answers On Stenting Vs. Surgery For Left-Main Disease
Executive Summary
NOBLE found that the five-year risk of major adverse events was higher after stenting compared to coronary bypass surgery to treat unprotected left-main coronary artery disease, while EXCEL found that stenting is safer than surgery in patients with this condition and low anatomic complexity.
You may also be interested in...
TCT 2017: PCI And CABG Yield Similar QOL Outcomes For Left-Main Disease
New results from the EXCEL trial, presented at the TCT conference in Denver, found that percutaneous coronary intervention and bypass graft surgery produce similar intermediate-term improvement in the quality-of-life scores of patients with left main coronary artery disease. The results are "testimony to how far PCI has come that it can now stand toe-to-toe with bypass surgery but also give patients a much more rapid recovery," one cardiologist said.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.